The objective of this study was to estimate the economic costs over the first 2 years of life of Group B Streptococcus (GBS) disease occurring in infants less than 90 days of age. A cost analysis was conducted using a prospective cohort of children born between 2000 and 2003 in the Greater London, Oxford, Portsmouth and Bristol areas of England. Unit costs were applied to estimates of the health and social resource use made by 138 infants diagnosed with GBS disease and 305 non-GBS controls matched for birth weight and hospital stay and time of birth. The health and social care costs for infants exposed to GBS disease were analysed in a multiple linear regression model. The mean health and social care cost over the first 2 years of life was estimated at £11,968.9 for infants with GBS, compared to £6,260.7 for the non-GBS controls; a mean cost difference of £5,708.1 (bootstrap 95% CI £2,977.1, £8,391.2, P = 0.03). After adjusting for gestational age and other potential confounders in a multiple linear regression, mean societal costs was £6,144.7 higher among GBS cases than among non-GBS controls (P < 0.001). This study shows that the health and social care costs for infants with GBS disease is, on average, two-fold higher during the first 2 years of life than for infants without GBS disease. These data should be used to inform policy decisions regarding the cost-effectiveness of prevention and treatment strategies for GBS disease during early childhood.
|Number of pages||11|
|Journal||European Journal of Health Economics|
|Publication status||Published - Jul 2009|
Bibliographical noteFunding Information:
The authors acknowledge the support of the Group B Streptococcus Working Group, chaired by Dr. Christine McCartney. The members of the Working Group are: Albert Mifsud, Alison Bedford-Russell, Androulla Efstratiou, Arlene Reynolds, Christine McCartney, Elizabeth Price, Liz Schroeder, Paul Heath, Rhona Hughes, Roy Fey, Stavros Petrou and Theresa Lamagni. The study was funded by a programme grant from the Meningitis Research Foundation. The sponsor had no role in study design; collection, analysis, and interpretation of data; writing of the report; or in the decision to submit the paper for publication.
- Cohort study
- Cost analysis
- Group B Streptococcus
- Health economics